Aortic stiffness increases upon receipt of anthracycline chemotherapy

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 166-172

  Chaosuwannakit, Narumol ^a   D'Agostino Jr , Ralph ^a   Hamilton, Craig A ^a   Lane, Kimberly S ^a   Ntim, William O ^a   Lawrence, Julia ^a   Melin, Susan A ^a   Ellis, Leslie R ^a   Torti, Frank M ^a   Little, William C ^a   Hundley, W Gregory ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE;

ADULT; AGE DISTRIBUTION; AGED; ARTERIAL STIFFNESS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE VOLUME; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERTENSION; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PULSE WAVE; SEX DIFFERENCE; THORACIC AORTA; AORTA; CASE CONTROL STUDY; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; ANTHRACYCLINES; AORTA; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 73949084826     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.8527     Document Type: Article

References (41)

1. Floyd JD, Nguyen DE, Lobins RL, et al: Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685-7696, 2005
2. Yeh ET, Tong AT, Lenihan DJ, et al: Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 109: 3122-3131, 2004
3. Gianni L, Herman EH, Lipshultz SE, et al: Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 26:3777-3784, 2008
4. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998
5. Chen MH, Kerkela R, Force T: Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapy. Circulation 118:84-95, 2008
6. Carver JR, Shapiro CL, Ng A, et al: American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J Clin Oncol 25: 3991-4008, 2007
7. Boutouyrie P, Tropeano AI, Asmar R, et al: Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension 39:10-15, 2002
8. Cruickshank K, Riste L, Anderson SG, et al: Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose tolerance: An integrated index of vascular function? Circulation 106:2085-2090, 2002
9. Sutton-Tyrrell K, Najar SS, Boudreau RM, et al: Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 111:3384-3390, 2005
10. Hundley WG, Kitzman DW, Morgan TM, et al: Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 38:796-802, 2001
11. Groenink M, de Roos A, Mulder BJ, et al: Changes in aortic distensibility and pulse wave velocity with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 82:203-208, 1998
12. Malayeri AA, Natori S, Bahrami H, et al: Relation of aortic wall thickness and distensibility to cardiovascular risk factors (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol 102:491-496, 2008
13. Hundley WG, Li HF, Hillis D, et al: Quantitation of cardiac output with velocity-encoding, phase-difference magnetic resonance imaging. Am J Cardiol 75:1250-1255, 1995
14. Hundley WG, Li HF, Lange RA, et al: Assessment of left-to-right intracardiac shunting by velocity-encoded, phase-difference magnetic resonance imaging: A comparison with oximetric and indicator dilution techniques. Circulation 91:2955-2960, 1995
15. Thiele H, Paetsch I, Schnackenburg B, et al: Improved accuracy of quantitative assessment of left ventricular volume and ejection fraction by geometric models with steady-state free precession. J Cardiovasc Magn Reson 4:327-339, 2002
16. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
17. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
18. Larson RA, Dodge RK, Bloomfield CD, et al: Treatment of biologically determined subsets of acute lymphoblastic leukemia in adults: Cancer and Leukemia Group B studies, in Buchner, T (ed): Acute Leukemias: VI. Prognostic Factors and Treatment Strategies. Berlin, Germany, Springer-Verlag, 1997, pp 677-680
19. Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 85:2025-2037, 1995
20. Fenaux P, Chastang C, Chevret S, et al: A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 94:1192-1200, 1999
21. Engert A, Franklin J, Eich HT, et al: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 Trial. J Clin Oncol 25:3495-3502, 2007
22. Straus DJ, Portlock CS, Qin J, et al: Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483-3489, 2004
23. Thomas DA, Faderl S, O'Brien S, et al: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569-1580, 2006
24. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
25. Jensen BV: Cardiotoxic consequences of anthracycline-containing treatment in patients with breast cancer. Semin Oncol 33:S15-S21, 2006 (suppl 8)
26. Hooning MJ, Botma A, Aleman BM, et al: Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99: 365-375, 2007
27. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003
28. Swerdlow AJ, Higgins CD, Smith P, et al: Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 99:206-214, 2007
29. Moser EC, Noordijk EM, van Leeuwen FE, et al: Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107:2912-2919, 2006
30. Girerd X, Laurent S, Pannier B, et al: Arterial distensibility and left ventricular hypertrophy in patients with sustained essential hypertension. Am Heart J 122:1210-1214, 1991
31. Vinereanu D, Nicolaides E, Boden L: Conduit arterial stiffness is associated with impaired left ventricular subendocardial function. Heart 89:449-450, 2003
32. Laurent S, Boutouyrie P, Asmar R, et al: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236-1241, 2001
33. Lakatta EG, Levy D: Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises: Part I. Aging arteries: A "set up" for vascular disease. Circulation 107:139-146, 2003
34. Duquaine D, Hirsch GA, Chakrabarti A, et al: Rapid-onset endothelial dysfunction with adriamycin : Evidence for a dysfunctional nitric oxide synthase. Vasc Med 8:101-107, 2003
35. Drímal J, Zúrová-Nedelcevová J, Knezl V, et al: Cardiovascular toxicity of first line chemotherapy agents: Doxorubicin, cyclophosphamide, streptozotocin and bevacizumab. Neuro Endocrinol Lett 27: 176-179, 2006 (suppl 2)
36. Wenzel DG, Cosma GN: A model system for measuring comparative toxicities of cardiotoxic drugs for cultured rat heart myocytes, endothelial cells and fibroblasts: II. Doxorubicin, 5-fluorouracil and cyclophosphamide. Toxicology 33:117-128, 1984
37. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 340:115-126, 1999
38. O'Rourke FM, Staessen JA, Viachopoulos C, et al: Clinical application of arterial stiffness: Definitions and reference values. Am J Hypertens 15:426-444, 2002
39. Carabello BA, Spann JF: The uses and limitations of end-systolic indexes of left ventricular function. Circulation 69:1058-1064, 1984
40. Grossman W, Braunwald E, Mann T, et al: Contractile state of the left ventricle in man as evaluated from end-systolic pressure-volume relation. Circulation 56:845-852, 1977
41. Stefanadis C, Stratos C, Boudoulas H, et al: Distensibility of the ascending aorta: Comparison of invasive and non-invasive techniques in healthy men and in men with coronary artery disease. Eur Heart J 11:990-996, 1990